Inactive Instrument

Five Prime Therapeutics, Inc.

Equities

FPRX

US33830X1046

Biotechnology & Medical Research

Five Prime Therapeutics, Inc Announces Promotes Helen Collins Om Senior Vice President and Chief Medical Officer to Executive Vice President and Chief Medical Officer

August 23, 2019 at 01:37 am IST

On August 20, 2019, the Board of Directors of Five Prime Therapeutics, Inc. promoted Helen Collins, M.D., from Senior Vice President and Chief Medical Officer to Executive Vice President and Chief Medical Officer, effective August 20, 2019.

Latest news about Five Prime Therapeutics, Inc.

Amgen's 2Q Profit Drops on Acquisition Write-off, Revenue Growth Beats Wall Street Target	04/21/04	DJ
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from S&P TMI Index	19/21/19	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from S&P Global BMI Index	19/21/19	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from S&P Biotechnology Select Industry Index	19/21/19	CI
Five Prime Therapeutics, Inc.(NasdaqGM:FPRX) dropped from NASDAQ Biotechnology Index	19/21/19	CI
Five Prime Therapeutics, Inc. Announces Board Changes	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2000 Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 3000 Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2500 Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2000 Value Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell Small Cap Completeness Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell Small Cap Comp Value Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2500 Value Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 3000 Value Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell Microcap Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 3000E Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 3000E Value Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell Microcap Value Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2000 Dynamic Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2500 Dynamic Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2000 Value-Dynamic Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2500 Value-Dynamic Index	16/21/16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from NASDAQ Composite Index	16/21/16	CI
Amgen Inc. completed the acquisition of Five Prime Therapeutics, Inc..	16/21/16	CI
FDA Approves Five Prime’s Request for Breakthrough Therapy Designation	16/21/16	CI

Chart Five Prime Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company's pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	116B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	23.89B
ARGENX SE	-3.00%	21.58B
GENMAB A/S	-8.52%	18.96B
BEIGENE, LTD.	-13.41%	16.33B
WUXI APPTEC CO., LTD.	-40.50%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.14B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.02B

Bio Therapeutic Drugs